Miguel Unda

Bilbao, PV, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Transcriptional network analysis of PTEN-protein-deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication.

Transcriptional network analysis of PTEN-protein-deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication.

Journal: Molecular oncology

Published: March 04, 2025

Transcriptional analysis of metastatic hormone-naïve prostate cancer primary tumor biopsies reveals a relevant role for SOX11 in prostate cancer cell dissemination.

Transcriptional analysis of metastatic hormone-naïve prostate cancer primary tumor biopsies reveals a relevant role for SOX11 in prostate cancer cell dissemination.

Journal: Genome biology

Published: August 07, 2024

Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer.

Optimizing triple therapy in patients with metastatic hormone-sensitive prostate cancer.

Journal: Actas urologicas espanolas

Published: June 05, 2024

Fibroblastic aspartoacylase suppresses TGFβ-mediated responses and cancer progression.

Fibroblastic aspartoacylase suppresses TGFβ-mediated responses and cancer progression.

Journal: Nature communications

Published: March 25, 2024

Why is it necessary to produce a BCG strain in Spain?

Why is it necessary to produce a BCG strain in Spain?

Journal: Actas urologicas espanolas

Published: January 12, 2024

Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors' reply.

Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors' reply.

Journal: Actas urologicas espanolas

Published: April 27, 2023

A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer.

A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer.

Journal: Actas urologicas espanolas

Published: December 15, 2022

METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer.

METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer.

Journal: Molecular cancer

Published: August 03, 2022

Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.

Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial.

Journal: European urology oncology

Published: May 18, 2022

PI3K-regulated Glycine N-methyltransferase is required for the development of prostate cancer.

PI3K-regulated Glycine N-methyltransferase is required for the development of prostate cancer.

Journal: Oncogenesis

Published: March 02, 2021

Clinical Implications of (Pro)renin Receptor (PRR) Expression in Renal Tumours.

Clinical Implications of (Pro)renin Receptor (PRR) Expression in Renal Tumours.

Journal: Diagnostics (Basel, Switzerland)

Published: December 07, 2020

Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma.

Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma.

Journal: Cancers

Published: November 27, 2020

Showing 1-12 of 40

Last Updated: 09/26/2026